LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
15.65
0.00 (0.00%)
Oct 29, 2025, 4:00 PM EDT - Market open

LB Pharmaceuticals Stock Forecast

Stock Price Forecast

The 3 analysts that cover LB Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $46.33, which forecasts a 196.04% increase in the stock price over the next year. The lowest target is $27 and the highest is $78.

Price Target: $46.33 (+196.04%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$27$46.33$34$78
Change+72.52%+196.04%+117.25%+398.40%

Analyst Ratings

The average analyst rating for LB Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingOct '25
Strong Buy1
Buy2
Hold0
Sell0
Strong Sell0
Total3

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Piper Sandler
Piper Sandler
Buy
Initiates
$78
BuyInitiates$78+398.40%Oct 6, 2025
Stifel
Stifel
Strong Buy
Initiates
$27
Strong BuyInitiates$27+72.52%Oct 6, 2025
Leerink Partners
Leerink Partners
Buy
Initiates
$34
BuyInitiates$34+117.25%Oct 6, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.14
from -250.61
EPS Next Year
-4.40
from -3.14
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
------
Revenue Growth
------
EPS
-62.09-25.14-250.61-3.14-4.40-3.71
EPS Growth
------
Forward PE
------
No. Analysts
---444
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
Highn/an/a
Avgn/an/a
Lown/an/a

Revenue Growth

Revenue Growth202520262027
High--
Avg--
Low--

EPS Forecast

EPS202520262027
High-2.82-3.52
Avg-3.14-4.40
Low-3.40-5.16

EPS Growth

EPS Growth202520262027
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.